These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 31985517)
1. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. Liberman P; Shifera AS; Berkenstock M Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517 [TBL] [Abstract][Full Text] [Related]
2. [Ocular symptoms associated with dupilumab in atopic dermatitis]. Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835 [TBL] [Abstract][Full Text] [Related]
3. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. Voorberg AN; den Dunnen WFA; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e64-e66. PubMed ID: 31465590 [No Abstract] [Full Text] [Related]
4. Conjunctivitis in dupilumab clinical trials. Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191 [TBL] [Abstract][Full Text] [Related]
5. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203 [TBL] [Abstract][Full Text] [Related]
6. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Bakker DS; Ariens LFM; van Luijk C; van der Schaft J; Thijs JL; Schuttelaar MLA; van Wijk F; Knol EF; Balak DMW; van Dijk MR; de Bruin-Weller MS Br J Dermatol; 2019 May; 180(5):1248-1249. PubMed ID: 30597515 [No Abstract] [Full Text] [Related]
7. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. Agnihotri G; Shi K; Lio PA Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936 [TBL] [Abstract][Full Text] [Related]
8. Cyclosporine 0.1% (Ikervis Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231 [TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin. Sernicola A; Gattazzo I; Di Staso F; Giordano D; Capalbo A; Persechino F; Scuderi G; Persechino S Dermatol Ther; 2019 Nov; 32(6):e13134. PubMed ID: 31639238 [TBL] [Abstract][Full Text] [Related]
10. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798 [TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. Treister AD; Kraff-Cooper C; Lio PA JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653 [TBL] [Abstract][Full Text] [Related]
12. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499 [TBL] [Abstract][Full Text] [Related]
13. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis. Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240 [TBL] [Abstract][Full Text] [Related]
14. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Nahum Y; Mimouni M; Livny E; Bahar I; Hodak E; Leshem YA Br J Ophthalmol; 2020 Jun; 104(6):776-779. PubMed ID: 31554632 [TBL] [Abstract][Full Text] [Related]
15. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients. Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603 [TBL] [Abstract][Full Text] [Related]
16. [Dupilumab-related blepharoconjunctivitis: Recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: Which management approach?]. Doan S; Arnould L; Febvay C; Fournié P; Gueudry J; Labalette P; Ouilhon C; Tran TH; Vabres B; Barbarot S; Bouaziz JD; Du-Thanh A; Jachiet M; Seneschal J; Soria A; Staumont-Sallé D; Baudouin C; Mortemousque B J Fr Ophtalmol; 2022 Mar; 45(3):277-287. PubMed ID: 35078645 [TBL] [Abstract][Full Text] [Related]
17. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471 [TBL] [Abstract][Full Text] [Related]
18. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients. Costedoat I; Wallaert M; Gaultier A; Vasseur R; Vanhaecke C; Viguier M; Cordelette C; Denoyer A; Ferrier le Bouëdec MC; Coutu A; Lamiaux M; Tran THC; Lacour JP; Elmaleh V; Tetart F; Gueudry J; Tauber M; Giordano-Labadie F; Cassagne M; Nosbaum A; Ouilhon C; Jachiet M; Tadayoni R; Dezoteux F; Staumont-Salle D; Bouleau J; Labalette P; Doan S; Soria A; Mortemousque B; Seneschal J; Barbarot S; J Eur Acad Dermatol Venereol; 2023 May; 37(5):1056-1063. PubMed ID: 36732052 [TBL] [Abstract][Full Text] [Related]